Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.39 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 2/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834680 | 0.88 | ACMSD (0.43) | CDK2HIF1APRSS12ALBXDH | |
| SCHEMBL6833960 | 0.88 | MCL1 (0.43) | CDK2HIF1APRSS12ALBXDH | |
| SCHEMBL6834186 | 0.87 | HIF1A (0.49) | CDK2HIF1APRSS12ALBXDH | |
| SCHEMBL6834495 | 0.87 | HIF1A (0.41) | CDK2HIF1APRSS12ALB | |
| SCHEMBL6817661 | 0.86 | PRSS12 (0.40) | CDK2PRSS12IDO1ALBXDH | |
| SCHEMBL6931399 | 0.86 | HIF1A (0.39) | CDK2HIF1APRSS12ALBMCL1 | |
| SCHEMBL6834124 | 0.85 | XDH (0.40) | HIF1APRSS12ALBXDHSLC22A12 | |
| SCHEMBL6830490 | 0.84 | HIF1A (0.55) | CDK2HIF1AALB | |
| SCHEMBL6833249 | 0.81 | MCL1 (0.41) | HIF1APRSS12ALBXDHSLC22A12 | |
| SCHEMBL6833104 | 0.80 | HIF1A (0.49) | CDK2HIF1APRSS12ALBXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | CDK2 4509/4885HIF1A 220/4885PRSS12 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.